We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

172 hedge funds and large institutions have $1.34B invested in Mirum Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 69 increasing their positions, 53 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 53

5.88% more ownership

Funds ownership: 108.37%114.24% (+5.9%)

7% less call options, than puts

Call options by funds: $1.79M | Put options by funds: $1.93M

8% less funds holding

Funds holding: 187172 (-15)

10% less capital invested

Capital invested by funds: $1.49B → $1.34B (-$155M)

36% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 36

43% less funds holding in top 10

Funds holding in top 10: 74 (-3)

Holders
172
Holders Change
-15
Holders Change %
-8.02%
% of All Funds
2.48%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.06%
New
23
Increased
69
Reduced
53
Closed
36
Calls
$1.79M
Puts
$1.93M
Net Calls
-$141K
Net Calls Change
-$873K
Name Holding Trade Value Shares
Change
Change in
Stake
FLSM
1
Frazier Life Sciences Management
California
$163M
BI
2
BVF Inc
California
$110M
EAM
3
Eventide Asset Management
Massachusetts
$82.9M +$17.5M +636,751 +24%
State Street
4
State Street
Massachusetts
$70.9M +$29.9M +1,087,697 +63%
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$69.5M +$19.4M +704,659 +34%
BlackRock
6
BlackRock
New York
$61.6M -$261K -9,477 -0.4%
CCM
7
Cadian Capital Management
New York
$57.6M +$9.83M +357,645 +18%
Vanguard Group
8
Vanguard Group
Pennsylvania
$55.6M -$7.27M -264,559 -11%
RSCM
9
Rock Springs Capital Management
Maryland
$46.6M +$140K +5,100 +0.3%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$40.1M +$11.9M +432,824 +37%
NHAS
11
Novo Holdings A/S
Denmark
$37.7M
Citadel Advisors
12
Citadel Advisors
Florida
$35M -$1.38M -50,306 -3%
TCM
13
Tang Capital Management
California
$29.8M +$1.37M +50,000 +4%
APM
14
Avidity Partners Management
Texas
$28.7M
FTM
15
First Turn Management
California
$24.1M +$3.36M +122,352 +15%
Pictet Asset Management
16
Pictet Asset Management
Switzerland
$24M +$4.46M +162,259 +20%
Franklin Resources
17
Franklin Resources
California
$23.6M +$778K +28,306 +3%
Goldman Sachs
18
Goldman Sachs
New York
$17.6M +$6.7M +243,798 +53%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$17.5M +$439K +15,959 +2%
William Blair Investment Management
20
William Blair Investment Management
Illinois
$15.8M +$151K +5,494 +0.9%
PCH
21
Polar Capital Holdings
United Kingdom
$15.7M
Axa
22
Axa
France
$14.9M +$2.01K +73 +0%
Millennium Management
23
Millennium Management
New York
$13.6M +$8.67M +315,290 +141%
PM
24
Prosight Management
Texas
$11.7M +$4.72M +171,699 +59%
BCM
25
Boone Capital Management
Georgia
$11.4M -$1.05M -38,241 -8%

MIRM Hedge Fund Activity: Q1 2024 in Review

172 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q1 2024, worth a combined $1.34B — down 10% from $1.49B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of MIRM and 23 opened new positions — a net loss of 13 holders — while 53 trimmed existing stakes and 69 added.

The largest buyer was State Street, adding an estimated $29.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $15.8M sold.

  • 172 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q1 2024, down from 187 in Q4 2023.
  • Funds reported $1.34B of Mirum Pharmaceuticals stock for Q1 2024, down 10% quarter-over-quarter.
  • 23 funds opened new Mirum Pharmaceuticals positions in Q1 2024 and 36 closed out, a net change of -13 holders.
  • The largest Mirum Pharmaceuticals buyer in Q1 2024 was State Street, an estimated $29.9M added.
  • The largest Mirum Pharmaceuticals seller in Q1 2024 was Perceptive Advisors, an estimated $15.8M sold.

Based on aggregated 13F filings for Q1 2024.